<DOC>
	<DOCNO>NCT01136759</DOCNO>
	<brief_summary>Tenofovir 1 % gel investigational vaginal microbicide intend reduce risk transmission HIV . Pregnant woman mother recently give birth often maintain sexual activity , research show may great risk HIV infection pregnancy . Microbicides may able prevent HIV infection pregnancy , would also prevent fetal exposure HIV . This study test safety use tenofovir 1 % gel healthy , pregnant woman healthy , breastfeeding woman .</brief_summary>
	<brief_title>Tenofovir Gel Pregnancy Lactation</brief_title>
	<detailed_description>Microbicides substance , like gel foam , develop apply intercourse prevent transmission HIV . Research show pregnant woman still risk sexual transmission HIV , research suggest pregnant woman may increase risk HIV infection . Microbicides may also aid prevent mother-to-child transmission HIV , might feasible alternative oral intravenous medication region method difficult implement . In test healthy woman vaginal microbicide tenofovir 1 % gel safe well tolerate . This study test safety tenofovir 1 % gel healthy , pregnant woman healthy , lactating woman . Participation study last approximately 3 10 week . Pregnant woman follow approximately 2 week delivery child , lactate woman follow 3 week . Pregnant woman give either tenofovir 1 % gel placebo gel apply daily 7 day . Groups pregnant woman divide accord late pregnancy enroll . Pregnant woman study visit enrollment , 6 day enrollment , delivery . They also participate phone assessment 1 , 3 , 14 day enrollment delivery . Lactating woman give tenofovir 1 % gel study visit enrollment 6 day enrollment . They also participate phone assessment 1 , 3 , 14 day enrollment . All participant complete blood test , physical exam , assessment adverse event .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Pregnancy cohort , inclusion criterion : Willing able provide write informed consent screen take part study , include participation infant delivery Willing able provide adequate locator information Willing able communicate write spoken English HIV uninfected Current pregnancy viable singleton Gestational age consistent follow guideline : For Pregnancy Cohort Group 1 , 37 0/7 39 1/7 week ( inclusive ) enrollment visit ( Day 0 ) For Pregnancy Cohort Group 2 , 34 0/7 36 6/7 week ( inclusive ) enrollment visit ( Day 0 ) Pap result consistent Grade 0 satisfactory evaluation nonGrade 0 Pap result , per clinical judgment site investigator record ( IoR ) /designee ) , 12 calendar month prior enrollment Willing abstain use nonprescribed intravaginal product practice ( include douche sex toy ) investigational agent device study participation Pregnancy cohort , exclusion criterion : History adverse reaction component tenofovir 1 % gel Enrollment investigational drug device trial within 30 day prior enrollment visit ( Day 0 ) Currently breastfeed Use vaginal medication within 48 hour prior screen enrollment ( Day 0 ) ( participant may return complete study procedure 48 hour pass since use vaginal medication ) Documented follow current pregnancy : Ultrasound evidence significant fetal congenital anomaly ( opinion IoR designee ) Known rupture amniotic membrane Known placental/fetal abnormality could affect placental transfer ( e.g. , placental abruption , placenta previa , placenta accreta , intrauterine growth restriction , twovessel cord , etc . ) Known maternal disease predictable negative effect placental function ( e.g. , hypertension , diabetes mellitus , collagen vascular disease ) Laboratory abnormality note screening , specify study protocol Diagnosis sexually transmit infection ( STI ) , include chlamydia , gonorrhea , and/or trichomoniasis , past 8 week prior enrollment ( Day 0 ) , assess participant report review medical record Symptomatic vaginitis , include bacterial vaginosis ( BV ) vulvovaginal candidiasis ( asymptomatic evidence BV and/or yeast exclusionary ) time enrollment ( Day 0 ) Clinically apparent pelvic exam find Grade 2 high ( observe study staff ) enrollment visit Use oral and/or vaginal preparation antibiotic antifungal medication screen within 7 day enrollment ( Day 0 ) Any social medical condition , investigator 's opinion , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective Lactation cohort , inclusion criterion : Willing able provide write informed consent screen take part study Willing able provide adequate locator information Willing able communicate speak write English HIV uninfected At enrollment , currently primarily breastfeed single healthy infant age 4 26 week ( inclusive ) Intending breastfeed period anticipate study participation Using effective method contraception enrollment ( Day 0 ) lactation cohort intend use effective method duration schedule study participation Pap result consistent Grade 0 satisfactory evaluation nonGrade 0 Pap result , per clinical judgment site IoR/designee , 12 calendar month prior enrollment ( Day 0 ) Willing abstain use nonprescribed intravaginal product practice ( include douche sex toy ) investigational agent device study participation Lactation cohort , mother exclusion criterion : Participation pregnancy cohort Infant exclude participation History adverse reaction component tenofovir 1 % gel Participation investigational drug device trial within 30 day prior enrollment visit ( Day 0 ) Use vaginal medication ( ) within 48 hour prior screen enrollment ( Day 0 ) ( participant may return complete study procedure 48 hour pass since use vaginal medication ) More two infant feeding single day nutrition breast milk ( e.g. , formula , solid ) within 7 day prior screen enrollment ( Day 0 ) At time enrollment ( Day 0 ) , participant report clinical evidence insufficient milk supply mastitis , accord judgment IoR/designee Any significant uncontrolled active chronic cardiovascular , renal , liver , hematologic , neurologic , gastrointestinal , psychiatric , endocrine , respiratory , immunologic disorder infectious disease , determine IoR/designee Certain laboratory result , specify study protocol Diagnosis STI , include chlamydia , gonorrhea , and/or trichomoniasis , 8 week prior enrollment ( Day 0 ) , assess participant report review medical record Symptomatic vaginitis , include BV vulvovaginal candidiasis ( asymptomatic evidence BV and/or yeast exclusionary ) time enrollment ( Day 0 ) Any follow finding enrollment : Incomplete postpartum involution uterus Clinically apparent Grade 2 high pelvic exam finding ( observe study staff ) Use oral and/or vaginal preparation antibiotic antifungal medication screen within 7 day enrollment ( Day 0 ) Any social medical condition , investigator 's opinion , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective Lactation cohort , infant inclusion criterion : Mother consent participation self infant lactation cohort In general good health , determine clinical judgment IoR/designee Between age 4 26 week ( inclusive ) screen enrollment Lactation cohort , infant exclusion criterion : Any social medical condition , investigator 's opinion , would make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Microbicide</keyword>
	<keyword>Mother-to-Child-Transmission</keyword>
	<keyword>Pregnancy</keyword>
</DOC>